Details of the Drug

General Information of Drug (ID: DM2HU9I)

Drug Name

Triamterene

Synonyms

Ademin; Ademine; Amteren; Anjal; Dazid; Diarol; Dinazide; Diren; Ditak; Diucelpin; Diurene; Diutensat; Diuteren; Dyberzide; Dyren; Dyrenium; Dytac; Dytenzide; Esiteren; Hidiurese; Hydrene; Hypertorr; Isobar; Jatropur; Jenateren; Kalspare; Masuharmin; Nephral; Noridil; Noridyl; Pterofen; Pterophene; Renezide; Reviten; Taturil; Teriam; Teridin; Triamizide; Triampur; Triamteren; Triamterena; Triamterenum; Triamteril; Triamterine; Triamthiazid; Tricilone; Trispan; Triteren; Triurene; Trizid; Turfa; Uretren; Urocaudal; Goldshield Brand of Triamterene; Jorba Brand of Triamterene; Pter ophene; SmithKline Beecham Brand of Triamterene; TRIAMTERENE USP; Thiazid Wolff; Triamteril complex; Wellspring Brand of Triamterene; Fluss 40; SKF 8542; T 4143; Ademin(e); Apo-triazide; Dyrenium (TN); Pteridine deriv. 11; SALI-PUREN; SK&F 8542; SK-8542; Tri-Span; Triamterena [INN-Spanish]; Triamterenum [INN-Latin]; SK&F-8542; Triamterene (JP15/USP/INN); Triamterene [USAN:INN:BAN:JAN]; 2,4,7-Triamino-6-fenilpteridina; 2,4,7-Triamino-6-fenilpteridina [Italian]; 2,4,7-Triamino-6-phenylpteridine; 6-PHENYL-2,4,7-TRIAMINO PTERIDINE; 6-Phenyl-2,4,7-pteridinetriamine; 6-Phenyl-2,4,7-triaminopteridine; 6-phenylpteridine-2,4,7-triamine

Indication

Disease Entry	ICD 11	Status	REF
Congestive heart failure	BD10	Approved	[1], [2], [3]
Edema	MG29	Approved	[1], [2], [3]
Hypertension	BA00-BA04	Approved	[1], [2], [3]

Therapeutic Class

Diuretics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

253.26

Topological Polar Surface Area (xlogp)

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 148.7 mcgh/L [4]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 46.4 mcg/L [4]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1.1 h [4]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [5]
Clearance: The total plasma clearance of drug is 4.5 L/min [6]
Elimination: Upon oral ingestion, somewhat less than 50% of the oral dose reaches the urine [7]
Half-life: The concentration or amount of drug in body reduced by one-half in 1.5 - 2 hours [7]
Metabolism: The drug is metabolized via the CYP1A2 to form 4'-hydroxytriamterene [4]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 13.14811 micromolar/kg/day [8]
Unbound Fraction: The unbound fraction of drug in plasma is 0.42% [9]
Vd: The volume of distribution (Vd) of drug is 1.49 L/kg [6]
Water Solubility: The ability of drug to dissolve in water is measured as 0.029 mg/mL [5]

Chemical Identifiers

Formula: C12H11N7
IUPAC Name: 6-phenylpteridine-2,4,7-triamine
Canonical SMILES: C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N
InChI: InChI=1S/C12H11N7/c13-9-7(6-4-2-1-3-5-6)16-8-10(14)18-12(15)19-11(8)17-9/h1-5H,(H6,13,14,15,17,18,19)
InChIKey: FNYLWPVRPXGIIP-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 5546
ChEBI ID: CHEBI:9671
CAS Number: 396-01-0
DrugBank ID: DB00384
TTD ID: D00NKB
VARIDT ID: DR01341
INTEDE ID: DR1636
ACDINA ID: D00700

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Amiloride-sensitive sodium channel (ENaC)	TTQM7TE	SCNNA_HUMAN; SCNNB_HUMAN; SCNNG_HUMAN; SCNND_HUMAN	Blocker	[10]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic cation transporter 1 (SLC22A1)	DTT79CX	S22A1_HUMAN	Substrate	[11]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 1A2 (CYP1A2)_{Main DME}	DEJGDUW	CP1A2_HUMAN	Substrate	[12]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Triamterene

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Spironolactone	DM2AQ5N	Major	Increased risk of hyperkalemia by the combination of Triamterene and Spironolactone.	Heart failure [BD10-BD1Z]	[36]
Eplerenone	DMF0NQR	Major	Increased risk of hyperkalemia by the combination of Triamterene and Eplerenone.	Heart failure [BD10-BD1Z]	[37]
Carvedilol	DMHTEAO	Moderate	Increased risk of hypertriglyceridemia by the combination of Triamterene and Carvedilol.	Heart failure [BD10-BD1Z]	[38]
Amiloride	DMRTSGP	Major	Increased risk of hyperkalemia by the combination of Triamterene and Amiloride.	Heart failure [BD10-BD1Z]	[36]
Digitoxin	DMWVIGP	Moderate	Increased risk of hypokalemia by the combination of Triamterene and Digitoxin.	Heart failure [BD10-BD1Z]	[39]
-----------

Coadministration of a Drug Treating the Disease Different from Triamterene (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Promazine	DMZAL7W	Moderate	Additive hypotensive effects by the combination of Triamterene and Promazine.	Appearance/behaviour symptom [MB23]	[40]
Linezolid	DMGFPU2	Moderate	Additive hypotensive effects by the combination of Triamterene and Linezolid.	Bacterial infection [1A00-1C4Z]	[41]
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Triamterene and Cariprazine.	Bipolar disorder [6A60]	[40]
Sotalol	DML60TN	Moderate	Increased risk of ventricular arrhythmias by the combination of Triamterene and Sotalol.	Cardiac arrhythmia [BC9Z]	[38]
Pentosan polysulfate	DM2HRKE	Moderate	Increased risk of hyperkalemia by the combination of Triamterene and Pentosan polysulfate.	Chronic pain [MG30]	[42]
Phenylbutazone	DMAYL0T	Moderate	Antagonize the effect of Triamterene when combined with Phenylbutazone.	Chronic pain [MG30]	[43]
Ketoprofen	DMRKXPT	Moderate	Antagonize the effect of Triamterene when combined with Ketoprofen.	Chronic pain [MG30]	[43]
Levomilnacipran	DMV26S8	Moderate	Increased risk of hyponatremia by the combination of Triamterene and Levomilnacipran.	Chronic pain [MG30]	[44]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Triamterene and Olopatadine.	Conjunctiva disorder [9A60]	[45]
Drospirenone	DM1A9W3	Moderate	Increased risk of hyperkalemia by the combination of Triamterene and Drospirenone.	Contraceptive management [QA21]	[46]
Ardeparin	DMYRX8B	Moderate	Increased risk of hyperkalemia by the combination of Triamterene and Ardeparin.	Coronary thrombosis [BA43]	[47]
Danaparoid	DM6CLBN	Moderate	Increased risk of hyperkalemia by the combination of Triamterene and Danaparoid.	Deep vein thrombosis [BD71]	[47]
Sertraline	DM0FB1J	Moderate	Increased risk of hyponatremia by the combination of Triamterene and Sertraline.	Depression [6A70-6A7Z]	[44]
Fluoxetine	DM3PD2C	Moderate	Increased risk of hyponatremia by the combination of Triamterene and Fluoxetine.	Depression [6A70-6A7Z]	[44]
Vilazodone	DM4LECQ	Moderate	Increased risk of hyponatremia by the combination of Triamterene and Vilazodone.	Depression [6A70-6A7Z]	[44]
Paroxetine	DM5PVQE	Moderate	Increased risk of hyponatremia by the combination of Triamterene and Paroxetine.	Depression [6A70-6A7Z]	[44]
Selegiline	DM6034S	Moderate	Additive hypotensive effects by the combination of Triamterene and Selegiline.	Depression [6A70-6A7Z]	[41]
Vortioxetine	DM6F1PU	Moderate	Increased risk of hyponatremia by the combination of Triamterene and Vortioxetine.	Depression [6A70-6A7Z]	[44]
Duloxetine	DM9BI7M	Moderate	Increased risk of hyponatremia by the combination of Triamterene and Duloxetine.	Depression [6A70-6A7Z]	[44]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Triamterene and Isocarboxazid.	Depression [6A70-6A7Z]	[41]
Milnacipran	DMBFE74	Moderate	Increased risk of hyponatremia by the combination of Triamterene and Milnacipran.	Depression [6A70-6A7Z]	[44]
Escitalopram	DMFK9HG	Moderate	Increased risk of hyponatremia by the combination of Triamterene and Escitalopram.	Depression [6A70-6A7Z]	[44]
Tranylcypromine	DMGB5RE	Moderate	Additive hypotensive effects by the combination of Triamterene and Tranylcypromine.	Depression [6A70-6A7Z]	[41]
Desvenlafaxine	DMHD4PE	Moderate	Increased risk of hyponatremia by the combination of Triamterene and Desvenlafaxine.	Depression [6A70-6A7Z]	[44]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Triamterene and OPC-34712.	Depression [6A70-6A7Z]	[40]
Phenelzine	DMHIDUE	Moderate	Additive hypotensive effects by the combination of Triamterene and Phenelzine.	Depression [6A70-6A7Z]	[41]
Carbamazepine	DMZOLBI	Moderate	Increased risk of hyponatremia by the combination of Triamterene and Carbamazepine.	Epilepsy/seizure [8A61-8A6Z]	[48]
Eslicarbazepine	DMZREFQ	Moderate	Increased risk of hyponatremia by the combination of Triamterene and Eslicarbazepine.	Epilepsy/seizure [8A61-8A6Z]	[49]
Nadolol	DMW6GVL	Moderate	Increased risk of ventricular arrhythmias by the combination of Triamterene and Nadolol.	Essential hypertension [BA00]	[38]
Mefenamic acid	DMK7HFI	Moderate	Antagonize the effect of Triamterene when combined with Mefenamic acid.	Female pelvic pain [GA34]	[43]
Cimetidine	DMH61ZB	Minor	Decreased elimination of Triamterene caused by Cimetidine mediated competitive inhibition of renal tubular secretion.	Gastro-oesophageal reflux disease [DA22]	[50]
Carteolol	DMFMDOB	Moderate	Increased risk of hypertriglyceridemia by the combination of Triamterene and Carteolol.	Glaucoma [9C61]	[38]
Metipranolol	DMJMVKI	Moderate	Increased risk of hyperglycemia by the combination of Triamterene and Metipranolol.	Glaucoma [9C61]	[38]
Levobunolol	DMTNFCQ	Moderate	Increased risk of hyperglycemia by the combination of Triamterene and Levobunolol.	Glaucoma [9C61]	[38]
Procarbazine	DMIK367	Moderate	Additive hypotensive effects by the combination of Triamterene and Procarbazine.	Hodgkin lymphoma [2B30]	[41]
Eprosartan	DM07K2I	Major	Increased risk of hyperkalemia by the combination of Triamterene and Eprosartan.	Hypertension [BA00-BA04]	[51]
Acebutolol	DM0TI4U	Moderate	Increased risk of hyperglycemia by the combination of Triamterene and Acebutolol.	Hypertension [BA00-BA04]	[38]
Aliskiren	DM1BV7W	Moderate	Increased risk of hyperkalemia by the combination of Triamterene and Aliskiren.	Hypertension [BA00-BA04]	[52]
Moexipril	DM26E4B	Major	Increased risk of hyperkalemia by the combination of Triamterene and Moexipril.	Hypertension [BA00-BA04]	[53]
Bisoprolol	DM3UZ95	Moderate	Increased risk of ventricular arrhythmias by the combination of Triamterene and Bisoprolol.	Hypertension [BA00-BA04]	[38]
Captopril	DM458UM	Major	Increased risk of hyperkalemia by the combination of Triamterene and Captopril.	Hypertension [BA00-BA04]	[53]
Trandolapril	DM4L6EU	Major	Increased risk of hyperkalemia by the combination of Triamterene and Trandolapril.	Hypertension [BA00-BA04]	[53]
Losartan	DM72JXH	Major	Increased risk of hyperkalemia by the combination of Triamterene and Losartan.	Hypertension [BA00-BA04]	[51]
Nebivolol	DM7F1PA	Moderate	Increased risk of hypertriglyceridemia by the combination of Triamterene and Nebivolol.	Hypertension [BA00-BA04]	[38]
Fosinopril	DM9NJ52	Major	Increased risk of hyperkalemia by the combination of Triamterene and Fosinopril.	Hypertension [BA00-BA04]	[53]
TAK-491	DMCF6SX	Major	Increased risk of hyperkalemia by the combination of Triamterene and TAK-491.	Hypertension [BA00-BA04]	[51]
Pindolol	DMD2NV7	Moderate	Increased risk of ventricular arrhythmias by the combination of Triamterene and Pindolol.	Hypertension [BA00-BA04]	[38]
Benazepril	DMH1M9B	Major	Increased risk of hyperkalemia by the combination of Triamterene and Benazepril.	Hypertension [BA00-BA04]	[53]
Enalapril	DMNFUZR	Major	Increased risk of hyperkalemia by the combination of Triamterene and Enalapril.	Hypertension [BA00-BA04]	[53]
Perindopril	DMOPZDT	Major	Increased risk of hyperkalemia by the combination of Triamterene and Perindopril.	Hypertension [BA00-BA04]	[53]
Quinapril	DMR8H31	Major	Increased risk of hyperkalemia by the combination of Triamterene and Quinapril.	Hypertension [BA00-BA04]	[53]
Telmisartan	DMS3GX2	Major	Increased risk of hyperkalemia by the combination of Triamterene and Telmisartan.	Hypertension [BA00-BA04]	[51]
Irbesartan	DMTP1DC	Major	Increased risk of hyperkalemia by the combination of Triamterene and Irbesartan.	Hypertension [BA00-BA04]	[54]
Lisinopril	DMUOK4C	Major	Increased risk of hyperkalemia by the combination of Triamterene and Lisinopril.	Hypertension [BA00-BA04]	[53]
Potassium chloride	DMMTAJC	Major	Increased risk of hyperkalemia by the combination of Triamterene and Potassium chloride.	Hypo-kalaemia [5C77]	[55]
Tolvaptan	DMIWFRL	Moderate	Increased risk of hyperkalemia by the combination of Triamterene and Tolvaptan.	Hypo-osmolality/hyponatraemia [5C72]	[56]
Meclofenamic acid	DM05FXR	Moderate	Antagonize the effect of Triamterene when combined with Meclofenamic acid.	Inflammatory spondyloarthritis [FA92]	[43]
Propiomazine	DMKY8V1	Moderate	Additive hypotensive effects by the combination of Triamterene and Propiomazine.	Insomnia [7A00-7A0Z]	[40]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Triamterene and ITI-007.	Insomnia [7A00-7A0Z]	[40]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Triamterene and Porfimer Sodium.	Lung cancer [2C25]	[57]
Propranolol	DM79NTF	Moderate	Increased risk of hypertriglyceridemia by the combination of Triamterene and Propranolol.	Migraine [8A80]	[38]
Ozanimod	DMT6AM2	Moderate	Additive hypotensive effects by the combination of Triamterene and Ozanimod.	Multiple sclerosis [8A40]	[41]
Prochlorperazine	DM53SRA	Moderate	Additive hypotensive effects by the combination of Triamterene and Prochlorperazine.	Nausea/vomiting [MD90]	[40]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Triamterene and Promethazine.	Nausea/vomiting [MD90]	[40]
Sibutramine	DMFJTDI	Moderate	Increased risk of hyponatremia by the combination of Triamterene and Sibutramine.	Obesity [5B80-5B81]	[44]
Rofecoxib	DM3P5DA	Moderate	Antagonize the effect of Triamterene when combined with Rofecoxib.	Osteoarthritis [FA00-FA05]	[43]
Valdecoxib	DMAY7H4	Moderate	Antagonize the effect of Triamterene when combined with Valdecoxib.	Osteoarthritis [FA00-FA05]	[43]
Diclofenac	DMPIHLS	Moderate	Antagonize the effect of Triamterene when combined with Diclofenac.	Osteoarthritis [FA00-FA05]	[43]
Naproxen	DMZ5RGV	Moderate	Antagonize the effect of Triamterene when combined with Naproxen.	Osteoarthritis [FA00-FA05]	[43]
Etodolac	DM6WJO9	Moderate	Antagonize the effect of Triamterene when combined with Etodolac.	Pain [MG30-MG3Z]	[43]
Diflunisal	DM7EN8I	Moderate	Antagonize the effect of Triamterene when combined with Diflunisal.	Pain [MG30-MG3Z]	[43]
Ibuprofen	DM8VCBE	Moderate	Antagonize the effect of Triamterene when combined with Ibuprofen.	Pain [MG30-MG3Z]	[43]
Nabumetone	DMAT2XH	Moderate	Antagonize the effect of Triamterene when combined with Nabumetone.	Pain [MG30-MG3Z]	[43]
Piroxicam	DMTK234	Moderate	Antagonize the effect of Triamterene when combined with Piroxicam.	Pain [MG30-MG3Z]	[43]
Safinamide	DM0YWJC	Moderate	Additive hypotensive effects by the combination of Triamterene and Safinamide.	Parkinsonism [8A00]	[41]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Triamterene and Rasagiline.	Parkinsonism [8A00]	[41]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Triamterene caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[58]
Ketorolac	DMI4EL5	Moderate	Antagonize the effect of Triamterene when combined with Ketorolac.	Postoperative inflammation [1A00-CA43]	[43]
Bromfenac	DMKB79O	Moderate	Antagonize the effect of Triamterene when combined with Bromfenac.	Postoperative inflammation [1A00-CA43]	[43]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Triamterene and Levomepromazine.	Psychotic disorder [6A20-6A25]	[40]
Fluphenazine	DMIT8LX	Moderate	Additive hypotensive effects by the combination of Triamterene and Fluphenazine.	Psychotic disorder [6A20-6A25]	[40]
Triflupromazine	DMKFQJP	Moderate	Additive hypotensive effects by the combination of Triamterene and Triflupromazine.	Psychotic disorder [6A20-6A25]	[40]
Meloxicam	DM2AR7L	Moderate	Antagonize the effect of Triamterene when combined with Meloxicam.	Rheumatoid arthritis [FA20]	[43]
Sulindac	DM2QHZU	Moderate	Antagonize the effect of Triamterene when combined with Sulindac.	Rheumatoid arthritis [FA20]	[43]
Celecoxib	DM6LOQU	Moderate	Antagonize the effect of Triamterene when combined with Celecoxib.	Rheumatoid arthritis [FA20]	[43]
Oxaprozin	DM9UB0P	Moderate	Antagonize the effect of Triamterene when combined with Oxaprozin.	Rheumatoid arthritis [FA20]	[43]
Flurbiprofen	DMGN4BY	Moderate	Antagonize the effect of Triamterene when combined with Flurbiprofen.	Rheumatoid arthritis [FA20]	[43]
Fenoprofen	DML5VQ0	Moderate	Antagonize the effect of Triamterene when combined with Fenoprofen.	Rheumatoid arthritis [FA20]	[43]
Tolmetin	DMWUIJE	Moderate	Antagonize the effect of Triamterene when combined with Tolmetin.	Rheumatoid arthritis [FA20]	[43]
Quetiapine	DM1N62C	Moderate	Additive hypotensive effects by the combination of Triamterene and Quetiapine.	Schizophrenia [6A20]	[40]
Mesoridazine	DM2ZGAN	Moderate	Additive hypotensive effects by the combination of Triamterene and Mesoridazine.	Schizophrenia [6A20]	[40]
Thioridazine	DM35M8J	Moderate	Additive hypotensive effects by the combination of Triamterene and Thioridazine.	Schizophrenia [6A20]	[40]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Triamterene and Aripiprazole.	Schizophrenia [6A20]	[40]
Iloperidone	DM6AUFY	Moderate	Additive hypotensive effects by the combination of Triamterene and Iloperidone.	Schizophrenia [6A20]	[40]
Paliperidone	DM7NPJS	Moderate	Additive hypotensive effects by the combination of Triamterene and Paliperidone.	Schizophrenia [6A20]	[40]
Loxapine	DM8AI9U	Moderate	Additive hypotensive effects by the combination of Triamterene and Loxapine.	Schizophrenia [6A20]	[40]
Haloperidol	DM96SE0	Moderate	Additive hypotensive effects by the combination of Triamterene and Haloperidol.	Schizophrenia [6A20]	[40]
Perphenazine	DMA4MRX	Moderate	Additive hypotensive effects by the combination of Triamterene and Perphenazine.	Schizophrenia [6A20]	[40]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Triamterene and Molindone.	Schizophrenia [6A20]	[40]
Chlorpromazine	DMBGZI3	Moderate	Additive hypotensive effects by the combination of Triamterene and Chlorpromazine.	Schizophrenia [6A20]	[40]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Triamterene and Thiothixene.	Schizophrenia [6A20]	[40]
Trifluoperazine	DMKBYWI	Moderate	Additive hypotensive effects by the combination of Triamterene and Trifluoperazine.	Schizophrenia [6A20]	[40]
Risperidone	DMN6DXL	Moderate	Additive hypotensive effects by the combination of Triamterene and Risperidone.	Schizophrenia [6A20]	[40]
Amisulpride	DMSJVAM	Moderate	Additive hypotensive effects by the combination of Triamterene and Amisulpride.	Schizophrenia [6A20]	[40]
Asenapine	DMSQZE2	Moderate	Additive hypotensive effects by the combination of Triamterene and Asenapine.	Schizophrenia [6A20]	[40]
Tacrolimus	DMZ7XNQ	Major	Increased risk of hyperkalemia by the combination of Triamterene and Tacrolimus.	Transplant rejection [NE84]	[59]
Trimethoprim	DMM7CHK	Major	Increased risk of hyperkalemia by the combination of Triamterene and Trimethoprim.	Urinary tract infection [GC08]	[60]
Methdilazine	DMAUHQX	Moderate	Additive hypotensive effects by the combination of Triamterene and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[40]
Trimeprazine	DMEMV9D	Moderate	Additive hypotensive effects by the combination of Triamterene and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[61]
-----------


⏷ Show the Full List of 109 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
D&C red no. 33	E00261	19116	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
--------------------


⏷ Show the Full List of 7 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Triamterene 100 mg capsule	100 mg	Oral Capsule	Oral
Triamterene 50 mg capsule	50 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4329).
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 071251.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4	DailyMed Label: DYRENIUM (triamterene) oral capsules
5	BDDCS applied to over 900 drugs
6	Gilfrich HJ, Kremer G, Mohrke W, Mutschler E, Volger KD: Pharmacokinetics of triamterene after i.v. administration to man: determination of bioavailability. Eur J Clin Pharmacol. 1983;25(2):237-41.
7	PRO-TRIAZIDE (Triamterene 50 mg and Hydrochlorothiazide 25 mg) - Product Monograph
8	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
10	Effects of the serine/threonine kinase SGK1 on the epithelial Na(+) channel (ENaC) and CFTR: implications for cystic fibrosis. Cell Physiol Biochem. 2001;11(4):209-18.
11	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
12	Rate-limiting biotransformation of triamterene is mediated by CYP1A2. Int J Clin Pharmacol Ther. 2005 Jul;43(7):327-34.
13	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
14	Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
15	Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
16	Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
17	PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
18	The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
19	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
20	The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
21	Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
22	Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
23	Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
24	Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
25	Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
26	Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
27	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
28	Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
29	Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
30	Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
31	Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
32	Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
33	The in vitro effect of nebulised hypertonic saline on human bronchial epithelium. Eur Respir J. 2018 May 17;51(5):1702652.
34	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 742).
35	Small molecule activator of the human epithelial sodium channel. J Biol Chem. 2008 May 2;283(18):11981-94.
36	Product Information. Aldactone (spironolactone). Searle, Skokie, IL.
37	Marcy TR, Ripley TL "Aldosterone antagonists in the treatment of heart failure." Am J Health Syst Pharm 63 (2006): 49-58. [PMID: 16373465]
38	Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA "Nadolol in combination with indapamide and xipamide in resistant hypertensives." Eur J Clin Pharmacol 28 (1985): 29-33. [PMID: 3987783]
39	Brown DD, Dormois JC, Abraham GN, et al "Effect of furosemide on the renal excretion of digoxin." Clin Pharmacol Ther 20 (1976): 395-400. [PMID: 975715]
40	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
41	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
42	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
43	Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
44	Product Information. Savella (milnacipran). Forest Pharmaceuticals, St. Louis, MO.
45	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
46	Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
47	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
48	Yassa R, Nastase C, Camille Y, Henderson M, Belzile L, Beland F "Carbamazepine, diuretics, and hyponatremia: a possible interaction." J Clin Psychiatry 48 (1987): 281-3. [PMID: 3597330]
49	Product Information. Aptiom (eslicarbazepine). Sunovion Pharmaceuticals Inc, Marlborough, MA.
50	Muirhead MR, Somogyi AA, Rolan PE, Bochner F "Effect of cimetidine on renal and hepatic drug elimination: studies with triamterene." Clin Pharmacol Ther 40 (1986): 400-7. [PMID: 3757403]
51	Product Information. Midamor (amiloride). Merck & Co, Inc, West Point, PA.
52	Product Information. Tekturna (aliskiren). Novartis Pharmaceuticals, East Hanover, NJ.
53	Jarman PR, Mather HM "Diabetes may be independent risk factor for hyperkalaemia." BMJ 327 (2003): 812. [PMID: 14525902]
54	Jarman PR, Kehely AM, Mather HM "Hyperkalaemia in diabetes: prevalence and associations." Postgrad Med J 71 (1995): 551-2. [PMID: 7479468]
55	McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970): 58-70. [PMID: 5410663]
56	Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
57	Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
58	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
59	Perazella MA "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med 109 (2000): 307-14. [PMID: 10996582]
60	Canaday DH, Johnson JR "Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole." Ann Intern Med 120 (1994): 438. [PMID: 8304666]
61	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.